source
- Genentech pays Alector $100M for preclinical Parkinson’s prospectGenentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.
- Stem cell advocates anticipate FDA roundtables as peptide therapies gain regulatory footholdAt PepMed 2026, a conference focused on peptide medicines, stem cell entrepreneur Chuck Meeker said he expects the FDA to hold a series of roundtables on regenerative therapies before year‑end. He…